The short version of amino acid sequence fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Concomitant use of pseudoephedrine with other vasoconstrictors, including ergot alkaloids like ergotamine and dihydroergotamine, linezolid, oxytocin, ephedrine, phenylephrine, and bromocriptine, among others, is not recommended due to the possibility of greater increases in blood pressure and risk of hemorrhagic stroke. Sympathomimetic effects and cardiovascular risks of pseudoephedrine may also be increased with digitalis glycosides, tricyclic antidepressants, appetite suppressants, and inhalational anesthetics. Likewise, greater sympathomimetic effects of pseudoephedrine may occur when it is combined with other sympathomimetic agents. Rare but serious cardiovascular complications have been reported with the combination of pseudoephedrine and bupropion. Increase of ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. The antihypertensive effects of methyldopa, guanethidine, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics like pseudoepehdrine. Beta blockers like labetalol may reduce the effects of pseudoephedrine. Urinary acidifying agents like ascorbic acid and ammonium chloride can increase the excretion of and thereby reduce exposure to amphetamines including pseudoephedrine, whereas urinary alkalinizing agents including antacids like sodium bicarbonate as well as acetazolamide can reduce the excretion of these agents and thereby increase exposure to them.
"Alsos Digital Library for Nuclear Issues – Plutonium". Washington and Lee University. Archived from the original on February 3, 2009. Retrieved February 15, 2009. Sutcliffe, W. G.; et al. (1995). "A Perspective on the Dangers of Plutonium". Lawrence Livermore National Laboratory. Archived from the original on September 29, 2006. "Physical, Nuclear, and Chemical, Properties of Plutonium". IEER. 2005. Retrieved February 15, 2009. "A History of Plutonium". Los Alamos National Laboratory. Retrieved July 8, 2023. Bhadeshia, H. "Plutonium crystallography". Samuels, D. (2005). "End of the Plutonium Age". Discover Magazine. 26 (11). Pike, J.; Sherman, R. (2000). "Plutonium production". Federation of American Scientists. Archived from the original on February 3, 2009. Retrieved February 15, 2009. "Plutonium Manufacture and Fabrication". Ong, C. (1999). "World Plutonium Inventories". Nuclear Files.org. Archived from the original on August 5, 2014. Retrieved February 15, 2009. "Challenges in Plutonium Science". Los Alamos Science. I & II (26). 2000. Retrieved February 15, 2009. "Plutonium". Royal Society of Chemistry. Retrieved February 6, 2015. "Plutonium". The Periodic Table of Videos. University of Nottingham. Retrieved February 6, 2015. Plutonium Fuel Fabrication by Argonne National Laboratory on YouTube
=== Use of the term biology === From Greek βίος (bíos) 'life', (from Proto-Indo-European root *gwei-, to live) and λογία (logia) 'study of'. The compound appears in the title of Volume 3 of Michael Christoph Hanow's Philosophiae naturalis sive physicae dogmaticae: Geologia, biologia, phytologia generalis et dendrologia, published in 1766. The term biology in its modern sense appears to have been introduced independently by Thomas Beddoes (in 1799), Karl Friedrich Burdach (in 1800), Gottfried Reinhold Treviranus (Biologie oder Philosophie der lebenden Natur, 1802) and Jean-Baptiste Lamarck (Hydrogéologie, 1802). Before biology, there were several terms used for the study of animals and plants. Natural history referred to the descriptive aspects of biology, though it also included mineralogy and other non-biological fields; from the Middle Ages through the Renaissance, the unifying framework of natural history was the scala naturae or Great Chain of Being. Natural philosophy and natural theology encompassed the conceptual and metaphysical basis of plant and animal life, dealing with problems of why organisms exist and behave the way they do, though these subjects also included what is now geology, physics, chemistry, and astronomy. Physiology and (botanical) pharmacology were the province of medicine. Botany, Zoology, and (in the case of fossils) Geology replaced natural history and natural philosophy in the 18th and 19th centuries before biology was widely adopted.
== Chemistry == LifeAct-TagGFP2 being the most widely used fluorescent variant compared to other LifeAct constructs is composed of the first 17 amino acid from the Saccharomyces cerevisiae Abp140, an actin-binding protein. The Abp140 is highly conserved among Saccharomyces cerevisiae and other closely related organisms. The 17 amino acid fragment of Abp140 was genetically fused to GFP and fluoresces green when it binds the F-actin structures of living and fixed cells, allowing for visualization of cell mechanics under microscopes. Previous experiments involving the analysis of cell mechanics had depended on fluorescently labeled phalloidin and actin GFP fusion proteins obtained from utrophin in Xenopus laevis and ABP120 in Dictyostelium discoideum. However, due to their large protein size, markers such as phalloidin and GFP fusion proteins are limited to cells that can be transfected and tend to compete with their orthologous protein. These localization markers affect cellular mechanical properties and F-actin structures, thus making these markers unreliable. An alternative to these markers is Life Act-TagGFP2, which is a much smaller protein and does not affect cell mechanics. Cells synthesize LifeAct-TagGFP2 in a short period of time making it suitable as a cost-effective in vivo marker.
Sources: en.wikipedia.org
Fabrication and coating of nanodevices and medical implants to increase biocompatibility. Emulsifiers in food industry and personal care products. Hydrophobins' high stability can be very useful in the coating of surfaces of prolonged use or under harsh conditions. The easy dissociation of a class II hydrophobin monolayer might be desirable and this can easily be achieved by the use of detergents and alcohols. The use of hydrophobins in protein purification, drug delivery and cell attachment has been reported. For more about the potential biotechnological applications of hydrophobins see Hektor & Scholtmeijer (2005) and Cox & Hooley (2009).
Phenol derivatives There are a number of glucosides found in natural phenols and polyphenols, as, for example, in the flavonoids chemical family. Arbutin, which occurs in bearberry along with methyl arbutin, hydrolyses to hydroquinone and glucose. Pharmacologically it acts as a urinary antiseptic and diuretic; Salicin, also termed Saligenin and glucose occurs in the willow. The enzymes ptyalin and emulsin convert it into glucose and saligenin, ortho-oxybenzylalcohol. Oxidation gives the aldehyde helicin.
== Central ideas == The hypercycle is a cycle of connected, self-replicating macromolecules. In the hypercycle, all molecules are linked such that each of them catalyses the creation of its successor, with the last molecule catalysing the first one. In such a manner, the cycle reinforces itself. Furthermore, each molecule is additionally a subject for self-replication. The resultant system is a new level of self-organization that incorporates both cooperation and selfishness. The coexistence of many genetically non-identical molecules makes it possible to maintain a high genetic diversity of the population. This can be a solution to the error threshold problem, which states that, in a system without ideal replication, an excess of mutation events would destroy the ability to carry information and prevent the creation of larger and fitter macromolecules. Moreover, it has been shown that hypercycles could originate naturally and that incorporating new molecules can extend them. Hypercycles are also subject to evolution and, as such, can undergo a selection process. As a result, not only does the system gain information, but its information content can be improved. From an evolutionary point of view, the hypercycle is an intermediate state of self-organization, but not the final solution. Over the years, the hypercycle theory has experienced many reformulations and methodological approaches. Among them, the most notable are applications of partial differential equations, cellular automata, and stochastic formulations of Eigen's problem.
Sources: en.wikipedia.org
== Pathophysiology == The cause of the disease is the lack of a fully functional insulin receptor, which has a profound effect during fetal development and thereafter. In one case, it was found (by culturing pancreatic cells) that the receptor produced by the mutant allele is only about 15% as effective as the normal receptor. The beta cells in the pancreas, which make and store insulin and release it on an as-needed basis, are often found to be very large or numerous. The role of insulin in the body is to facilitate the entrance of glucose into the cell. Once insulin binds to the insulin receptors on the cell surface, the insulin receptors will send a signal that will ultimately bring the glucose transporter protein GLUT4 to attach to the cell membrane. Additionally, once insulin is bound to the insulin receptors, it will also initiate several signaling cascades that will promote cell growth and differentiation, protein synthesis, glucose synthesis, and the inhibition of gluconeogenesis through several metabolic pathways. A malfunctioning insulin receptor would thus not be able to properly initiate the signaling cascades for the aforementioned cellular processes. Many of the problems associated with Donohue syndrome may be due to the insulin receptor binding the insulin-like growth factor, regulating the growth of the embryo, in addition to its well-known role in the regulation of blood sugar.
Menkes disease is a congenital disease that is a cause of copper deficiency. Menkes disease is a hereditary condition caused by a defective gene involved with the metabolism of copper in the body. Menkes disease has a wide variety of symptoms including floppy muscle tone, seizures, abnormally low body temperature, and a peculiar steel color hair that feels very rough. Menkes disease is usually fatal, with the majority of affected children dying within the first ten years of life.
When an ice road is part of a winter road, as is commonly the case, its design and construction is comprised within the overall road planning, i.e. in conjunction with the over-land segments. Either way, factors that need to be addressed before construction include the following:
Instead the liver is strongly stimulated to manufacture glucose from glycogen (through glycogenolysis) and from non-carbohydrate sources (such as lactate and de-aminated amino acids) using a process known as gluconeogenesis. The glucose thus produced is discharged into the blood correcting the detected error (hypoglycemia). The glycogen stored in muscles remains in the muscles, and is only broken down, during exercise, to glucose-6-phosphate and thence to pyruvate to be fed into the citric acid cycle or turned into lactate. It is only the lactate and the waste products of the citric acid cycle that are returned to the blood. The liver can take up only the lactate, and, by the process of energy-consuming gluconeogenesis, convert it back to glucose.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.